ACLX
Arcellx, Inc.Company Information
- Company Name
- Arcellx, Inc.
- CIK
- CIK0001786205
- Category
- Large accelerated filer
- Ticker: Exchange
- ACLX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ACLX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-02-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 206,566
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 51,505,365
- Shares outstanding
- 56,305,535
- Ownership
- 91.47%
Earnings Market Reaction
- Filing date
- 2026-02-26
- Price on filing date
- —
- 1-month reaction
- 0.78%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 80 | 79 | 62 | 81 | 106 | 162 | 100 | 155 | 395 | 126 | 304 | 275 | ||||||
| Marketable Securities Current | 370 | 382 | 391 | 462 | 482 | 412 | 417 | 419 | 307 | 314 | 203 | 259 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 462 | 472 | 464 | 554 | 599 | 587 | 530 | 589 | 716 | 491 | 558 | 571 | ||||||
| Due From Related Parties Current | - | - | - | - | - | - | - | - | - | - | 29 | 21 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 12 | 11 | 11 | 11 | 12 | 13 | 13 | 15 | 12 | 20 | 22 | 17 | ||||||
| Restricted Cash Noncurrent | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 3 | 3 | ||||||
| Marketable Securities Noncurrent | 70 | 115 | 85 | 22 | 38 | 102 | 130 | 117 | 27 | 43 | - | - | ||||||
| Property Plant And Equipment Net | 43 | 43 | 44 | 46 | 46 | 47 | 46 | 45 | 43 | 38 | 22 | 14 | ||||||
| Operating Lease Right Of Use Asset | 24 | 23 | 23 | 24 | 24 | 24 | 24 | 24 | 27 | 29 | 29 | 30 | ||||||
| Prepaid Expense Other Noncurrent | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 9 | 8 | 11 | 5 | ||||||
| Assets | 604 | 656 | 619 | 648 | 711 | 765 | 734 | 780 | 825 | 614 | 624 | 623 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 6 | 4 | 2 | 4 | 2 | 6 | 5 | 3 | 3 | 7 | 6 | 5 | ||||||
| Accrued Liabilities Current | 35 | 47 | 53 | 43 | 57 | 43 | 42 | 34 | 18 | 17 | 12 | 14 | ||||||
| Operating Lease Liability Current | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 7 | 6 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 104 | 118 | 122 | 112 | 125 | 137 | 88 | 108 | 118 | 173 | 156 | 166 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 11 | 19 | 33 | 39 | 48 | 38 | 35 | ||||||
| Contract With Customer Liability Current | 56 | 60 | 59 | 57 | 59 | 70 | 15 | 31 | 51 | 94 | 94 | 107 | ||||||
| Operating Lease Liability Noncurrent | 44 | 44 | 45 | 46 | 47 | 47 | 48 | 48 | 51 | 48 | 41 | 32 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 6 | 9 | 15 | ||||||
| Contract With Customer Liability Noncurrent | 53 | 52 | 60 | 69 | 76 | 83 | 96 | 112 | 171 | 121 | 124 | 106 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 3 | 9 | 15 | 15 | 15 | - | - | - | - | ||||||
| Liabilities | 202 | 215 | 227 | 231 | 257 | 282 | 247 | 283 | 340 | 348 | 330 | 319 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,127 | 1,108 | 1,004 | 975 | 951 | 931 | 912 | 894 | 874 | 675 | 664 | 650 | ||||||
Stockholders Equity | ||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 0 | 1 | 1 | 2 | -1 | -1 | 1 | -0 | -0 | 0 | ||||||
| Stockholders Equity | 402 | 441 | 392 | 417 | 455 | 483 | 487 | 497 | 485 | 266 | 294 | 304 | ||||||
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | ||||||||||||||||||
| Retained Earnings Accumulated Deficit | -726 | -668 | -612 | -559 | -497 | -450 | -424 | -397 | -389 | -409 | -370 | -346 | ||||||
| Liabilities And Stockholders Equity | 604 | 656 | 619 | 648 | 711 | 765 | 734 | 780 | 825 | 614 | 624 | 623 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | - | 0.00 | 0.00 | - | - | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | - | - | 200 | 200 | - | - | - | - | 200 | 200 | 200 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | - | - | 0 | 0 | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 58 | 58 | 55 | 55 | 54 | 54 | 54 | 53 | 52 | 49 | 48 | 48 | ||||||
| Shares Outstanding | 58 | 58 | 55 | 55 | 54 | 54 | 54 | 53 | 52 | 49 | 48 | 48 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialArcellx, Inc. (ACLX) — SEC Financial Statements & Analysis
Arcellx, Inc. (ACLX) is a biological products, (no diagnostic substances) company, incorporated in DE. Arcellx, Inc. trades on Nasdaq as: ACLX. Arcellx, Inc. (ACLX)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-26. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), On profitability, Arcellx, Inc. posts an operating margin of -1135.61%, a net margin of -1027.25%, a Return on Equity (ROE) of -53.42%, a Return on Assets (ROA) of -34.81%, and a Return on Invested Capital (ROIC) of -75.66%. Per share, it reports EPS of $-4.07, diluted EPS of $-4.07, free cash flow per share of $-3.78, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -79.35% year-over-year, net income growth of 113.26% year-over-year, and EPS growth of 102.89% year-over-year. On the balance sheet, it maintains a current ratio of 4.44x, a quick ratio of 4.32x, working capital of $357.98M, a debt-to-equity ratio of 0.50x, a debt ratio of 0.33, an interest coverage ratio of -325.87x, free cash flow of $-212.59M (TTM), and net debt of $-82.88M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-4.07
- ROE TTM
- -53.42%
- ROA TTM
- -34.81%
- Debt To Equity
- 0.50x
- Free Cash Flow TTM
- $-212.59M
- Net Revenue TTM Growth 1Y
- -79.35%
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Arcellx, Inc. in?
Arcellx, Inc. (ACLX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ACLX trade on?
Arcellx, Inc. (ACLX) trades on the Nasdaq.
Where is Arcellx, Inc. incorporated?
Arcellx, Inc. is incorporated in DE.
When was Arcellx, Inc. (ACLX)'s most recent SEC filing?
Arcellx, Inc. (ACLX)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-26.
What is ACLX's EPS (earnings per share)?
Arcellx, Inc. (ACLX)'s trailing twelve month EPS is $-4.07 as of 2025-12-31.
What is ACLX's ROE (return on equity)?
Arcellx, Inc. (ACLX)'s trailing twelve month Return on Equity (ROE) is -53.42% as of 2025-12-31.
What is ACLX's ROA (return on assets)?
Arcellx, Inc. (ACLX)'s trailing twelve month Return on Assets (ROA) is -34.81% as of 2025-12-31.
What is ACLX's ROIC (return on invested capital)?
Arcellx, Inc. (ACLX)'s trailing twelve month Return on Invested Capital (ROIC) is -75.66% as of 2025-12-31.